Corporate Profile

CinCor is a clinical-stage biopharmaceutical company with a mission to dramatically improve the treatment paradigm for patients suffering from hypertension and other cardio-renal diseases. Its lead asset, CIN-107, is a first-in-class, highly selective oral small molecule aldosterone synthase inhibitor, which is in clinical development for hypertension and other cardio-renal diseases.

News Releases
News Release
CinCor Pharma Appoints June Lee to Its Board of Directors
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served
News Release
CinCor Pharma Announces Pricing of Initial Public Offering
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its
Events
More events are coming soon.

Latest quarterly results

Show all

More quarterly results coming soon.